Research ArticleArticle
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting
Philip J. Mease, Leonard H. Calabrese, Kristina Callis Duffin, Rebecca H. Haberman, Rodrigo Firmino, Jose U. Scher, Lori Schick, Kevin Winthrop and Joseph F. Merola
The Journal of Rheumatology March 2021, jrheum.201671; DOI: https://doi.org/10.3899/jrheum.201671
Philip J. Mease
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Leonard H. Calabrese
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Kristina Callis Duffin
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Rebecca H. Haberman
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Rodrigo Firmino
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Jose U. Scher
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Lori Schick
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Kevin Winthrop
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Joseph F. Merola
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. RH has received funding from the National Psoriasis Foundation, NIH/ NIAMS T32AR069515, The Riley Family Foundation, The Snyder Family Foundation, Bloomberg Philanthropies Covid-19 Response Initiative Grant, and the Rheumatology Research Foundation. 1P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/ Providence St. Joseph Health and University of Washington School of Medicine, Seattle, Washington; 2L.H. Calabrese, DO, Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Cleveland Clinic, Cleveland, Ohio; 3K. Callis Duffin, MD, MS, Professor and Chair, Department of Dermatology, University of Utah, Salt Lake City, Utah; 4R. Haberman, MD, MSCI, Clinical Instructor, Department of Medicine, Division of Rheumatology, NYU Grossman School of Medicine, New York, New York; 5R. Firmino, GRAPPA Patient Research Partner; 6J.U. Scher, MD, Department of Medicine, NYU Grossman School of Medicine, New York, New York; 7L. Schick, GRAPPA Patient Research Partner; 8K. Winthrop, MD, MPH, Oregon Health & Science University- Portland State University School of Public Health, Portland, Oregon; 9J.F. Merola, MD, MMSc, Harvard Medical School, Brigham and Women’s Hospital, Department of Dermatology and Department of Medicine, Division of Rheumatology and Immunology, Boston, Massachusetts, USA. The authors report the following conflicts of interest: PJM with AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, SUN Pharma, and UCB; KCD with Amgen, AbbVie, Celgene, Eli Lilly, Janssen, Bristol Myers Squibb, Stiefel, Novartis, Pfizer, Sienna, UCB, Regeneron, Boehringer Ingelheim, and Ortho Dermatologic; RH with Janssen; JUS with AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, and UCB; KW with Pfizer, AbbVie, UCB, Eli Lilly, Galapagos, GlaxoSmithKline, Roche, Gilead, Regeneron, Sanofi, AstraZeneca, Novartis, and BMS; JFM with Merck, Bristol Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and Leo Pharma. LHC, LS, and RF declare no conflicts. Address correspondence to Dr. P.J. Mease, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Seattle, WA 98122, USA. Email: pmease@philipmease.com.
Abstract
The coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic has affected the healthcare system on a global scale, and we utilized the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 annual meeting to examine how COVID-19 might affect patients with psoriatic disease (PsD) and the clinicians who care for them. Pressing issues and concerns identified included whether having psoriasis increased the risk of acquiring COVID-19, vaccine safety, and the acceptability of telehealth. The general message from rheumatologists, dermatologists, infectious disease specialists, and patient research partners was that data did not suggest that having PsD or its treatment significantly increased risk of infection or more severe disease course, and that the telehealth experience was a success overall.
In this issue
The Journal of Rheumatology
Vol. 49, Issue 5
1 May 2022
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting
Philip J. Mease, Leonard H. Calabrese, Kristina Callis Duffin, Rebecca H. Haberman, Rodrigo Firmino, Jose U. Scher, Lori Schick, Kevin Winthrop, Joseph F. Merola
The Journal of Rheumatology Mar 2021, jrheum.201671; DOI: 10.3899/jrheum.201671
Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting
Philip J. Mease, Leonard H. Calabrese, Kristina Callis Duffin, Rebecca H. Haberman, Rodrigo Firmino, Jose U. Scher, Lori Schick, Kevin Winthrop, Joseph F. Merola
The Journal of Rheumatology Mar 2021, jrheum.201671; DOI: 10.3899/jrheum.201671
